Poor
Not Aligned
Patient Risk:
Low
Summary
Only the labeled indication (partially, due to missing explicit 'mealtime' wording in provided excerpts) and that FIASP is insulin aspart are supported. Multiple other claims are not supported by the provided FDA label sections, including comparative absorption/effect versus NovoLog, all pricing/cost/patient assistance statements, and patent/biosimilar/market-effect statements.
Category Scores
Accurate Statements
Fiasp is a formulation of insulin aspart.
Supported by Label 11 DESCRIPTION stating FIASP (insulin aspart) injection.
Fiasp is a rapid-acting mealtime insulin used to improve glycemic control in adults and children with diabetes mellitus.
Partially supported by Label 1 INDICATIONS AND USAGE: improve glycemic control in adult and pediatric patients with diabetes mellitus. The provided label excerpt does not explicitly use the term/characterization 'mealtime' as such.
Unsupported Statements
Fiasp is absorbed faster than NovoLog insulin aspart.
No head-to-head comparison versus NovoLog insulin aspart is provided in the provided label sections; only FIASP absorption timing is described.
Fiasp has an earlier and more pronounced effect compared to NovoLog insulin aspart.
No comparative statements versus NovoLog insulin aspart are present in the provided label sections.
The list price for Fiasp can be substantial.
No pricing information appears in the provided FDA label sections.
Out-of-pocket costs for Fiasp can be reduced through insurance plans, discount programs, and patient assistance programs offered by the manufacturer, Novo Nordisk.
No statements about insurance/discount programs or manufacturer patient assistance appear in the provided label sections.
Prices for Fiasp can range from tens to hundreds of dollars per vial or pen before any discounts or insurance benefits are applied.
No specific pricing ranges appear in the provided FDA label sections.
Fiasp's price can be higher than older, generic insulin options.
No comparative pricing versus generics appears in the provided FDA label sections.
Information regarding the patents for Fiasp and insulin aspart can be found through patent tracking resources like DrugPatentWatch.com.
Patent sourcing/tracking resources are not addressed in the provided FDA label sections.
DrugPatentWatch.com lists patents related to Fiasp, providing details on their status and expiration.
No patent list/status/expiration content appears in the provided FDA label sections.
Following the expiration of relevant patents, biosimilar versions of Fiasp could potentially be developed and brought to market.
No discussion of patents, patent expiration, or biosimilar development/market entry appears in the provided FDA label sections.
Biosimilars are biological products that are highly similar to an already approved biological product.
No definition of biosimilars appears in the provided FDA label sections.
Biosimilars are claimed to have no clinically meaningful differences in terms of safety, purity, and potency.
No biosimilar safety/purity/potency claims appear in the provided FDA label sections.
The introduction of biosimilars often leads to increased competition and potentially lower prices for patients.
No statements about biosimilar market effects or pricing appear in the provided FDA label sections.
Contradictions
Important Omissions
Dosage and administration details (e.g., dosing regimen, titration, timing relative to meals) and core safety warnings/contraindications are not present in the claim set and therefore could not be aligned/validated against the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are largely non-clinical (pricing, patents, biosimilar market effects) and comparative marketing statements. No explicit contraindication, boxed-warning, or dosing-safety claims were made in the provided claim list.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label sections, especially head-to-head comparisons vs NovoLog and all pricing/patent/biosimilar/market-effect assertions.
Suggested Improvement
Limit statements to what is supported by the provided label excerpts (e.g., labeled indication and composition). Remove all pricing, patent tracking, biosimilar, and NovoLog comparative absorption/effect claims unless the provided label contains explicit support for those specific comparisons/statements.